Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Aclaris Therapeutics, Inc. (NASDAQ: ACRS)
ACRS Stock Predictions and Ratings
WSX Rating:
STRONG SELL
WSX Forecast (1yr):
-22.20%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
157.90%
ACRS Stock Analysis
ACRS
PE Ratio:
ACRS
PEG Ratio:
Not Available
ACRS
Forward EPS Growth (12 month):
0.00%
ACRS
PS Ratio:
63.7
ACRS
PSG Ratio:
-10.8
ACRS
Forward Revenue Growth (12 month):
-5.90%
ACRS Articles
No data was found